The collaboration will focus on advancing the potential drug candidate—formerly known as VIS513—through Phase III clinical ...

Case study highlights how clinical operations teams can overcome complex regulatory and operational hurdles to finish a trial ...

Hyderabad based vaccine maker Bharat Biotech International Limited (BBIL) has in-licensed a potential vaccine candidate for ...

The Serum Institute of India (SII), the world’s largest vaccine manufacturer and Drugs for Neglected Diseases initiative ...

Key Takeaways AI accelerates drug approvals in 2025 by streamlining clinical data analysis.Advanced AI tools reduce costs and time for new medicine development.

As India enters peak season for fungal infections, a breakthrough in natural medicine is making headlines: Skin Revive, a ...

Glenmark Pharmaceuticals to launch Brukinsa (zanubrutinib) in India after DCGI approval, offering treatment for five B-cell ...

Unlike donated blood, these artificial cells have no blood type, eliminating the need for any compatibility, making them ...

Glenmark Pharma to launch DCGI-approved Brukinsa in India to advance treatment of haematological malignancies: Our Bureau, Mumbai Monday, June 9, 2025, 14:30 Hrs [IST] Glenmark Ph ...

Glenmark will introduce Brukinsa, a BTK inhibitor developed by BeOne Medicines, in India after DCGI approval to treat five ...